| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kyle Arsenault-Mehta, Mario Hochman-Bérard, Alexander Johnson, Dar'ya Semenova, Bea Nguyen, Jessie Willis, Natalia Mouravska, Ridha Joober, Naista Zhan. Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review. Neuropsychopharmacology reports. 2023-10-05. PMID:37794723. |
available treatment options for schizophrenia including dopamine antagonists and traditional antipsychotic medications have not been shown to confer significant benefits on cognitive deficits. |
2023-10-05 |
2023-10-07 |
Not clear |
| Sunil Srivastav, Xiaoying Cui, Roger Bitencourt Varela, James P Kesby, Darryl Eyle. Increasing dopamine synthesis in nigrostriatal circuits increases phasic dopamine release and alters dorsal striatal connectivity: implications for schizophrenia. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-10-05. PMID:37798312. |
increasing dopamine synthesis in nigrostriatal circuits increases phasic dopamine release and alters dorsal striatal connectivity: implications for schizophrenia. |
2023-10-05 |
2023-10-07 |
rat |
| Sunil Srivastav, Xiaoying Cui, Roger Bitencourt Varela, James P Kesby, Darryl Eyle. Increasing dopamine synthesis in nigrostriatal circuits increases phasic dopamine release and alters dorsal striatal connectivity: implications for schizophrenia. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-10-05. PMID:37798312. |
one of the most robust neurochemical abnormalities reported in patients with schizophrenia is an increase in dopamine (da) synthesis and release, restricted to the dorsal striatum (ds). |
2023-10-05 |
2023-10-07 |
rat |
| Sunil Srivastav, Xiaoying Cui, Roger Bitencourt Varela, James P Kesby, Darryl Eyle. Increasing dopamine synthesis in nigrostriatal circuits increases phasic dopamine release and alters dorsal striatal connectivity: implications for schizophrenia. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-10-05. PMID:37798312. |
to understand the implications of this progressive neurobiology on brain function, we have developed a model in rats which we refer to as edips (enhanced dopamine in prodromal schizophrenia). |
2023-10-05 |
2023-10-07 |
rat |
| Leonardo Sportelli, Daniel P Eisenberg, Roberta Passiatore, Enrico D'Ambrosio, Linda A Antonucci, Qiang Chen, Jasmine Czarapata, Aaron L Goldman, Michael Gregory, Kira Griffiths, Thomas M Hyde, Joel E Kleinman, Antonio F Pardiñas, Madhur Parihar, Teresa Popolizio, Antonio Rampino, Joo Heon Shin, Mattia Veronese, William S Ulrich, Caroline F Zink, Alessandro Bertolino, Oliver D Howes, Karen F Berman, Daniel R Weinberger, Giulio Pergol. Dopamine and schizophrenia from bench to bedside: Discovery of a striatal co-expression risk gene set that predicts in vivo measures of striatal function. bioRxiv : the preprint server for biology. 2023-10-03. PMID:37786720. |
dopamine and schizophrenia from bench to bedside: discovery of a striatal co-expression risk gene set that predicts in vivo measures of striatal function. |
2023-10-03 |
2023-10-07 |
Not clear |
| Yoshifumi Abe, Sho Yagishita, Hiromi Sano, Yuki Sugiura, Masanori Dantsuji, Toru Suzuki, Ayako Mochizuki, Daisuke Yoshimaru, Junichi Hata, Mami Matsumoto, Shu Taira, Hiroyoshi Takeuchi, Hideyuki Okano, Nobuhiko Ohno, Makoto Suematsu, Tomio Inoue, Atsushi Nambu, Masahiko Watanabe, Kenji F Tanak. Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia. Cell reports. Medicine. 2023-09-29. PMID:37774703. |
dyskinesia is involuntary movement caused by long-term medication with dopamine-related agents: the dopamine agonist 3,4-dihydroxy-l-phenylalanine (l-dopa) to treat parkinson's disease (l-dopa-induced dyskinesia [lid]) or dopamine antagonists to treat schizophrenia (tardive dyskinesia [td]). |
2023-09-29 |
2023-10-07 |
mouse |
| Laoise Casserly, Daniel R Garton, Ana Montaño-Rodriguez, Jaan-Olle Andresso. Analysis of Acute and Chronic Methamphetamine Treatment in Mice on Gdnf System Expression Reveals a Potential Mechanism of Schizophrenia Susceptibility. Biomolecules. vol 13. issue 9. 2023-09-28. PMID:37759827. |
the increase in presynaptic striatal dopamine is the main dopaminergic abnormality in schizophrenia (scz). |
2023-09-28 |
2023-10-07 |
mouse |
| Lejia Fan, Liangbing Liang, Yujue Wang, Xiaoqian Ma, Liu Yuan, Lijun Ouyang, Ying He, Zongchang Li, Chunwang Li, Xiaogang Chen, Lena Palaniyappa. Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-09-26. PMID:37752221. |
a subgroup of patients with schizophrenia is believed to have aberrant excess of glutamate in the frontal cortex; this subgroup is thought to show poor response to first-line antipsychotic treatments that focus on dopamine blockade. |
2023-09-26 |
2023-10-07 |
Not clear |
| Pukar Khanal, Vishal S Patil, B M Patil, Kunal Bhattacharya, Amit Kumar Shrivastava, Raushan K Chaudhary, Lokjan Singh, Prarambh Sr Dwivedi, Darasaguppe R Harish, Subarna Ro. The marijuana-schizophrenia multifaceted nexus: Connections and conundrums towards neurophysiology. Computational biology and chemistry. vol 107. 2023-09-20. PMID:37729848. |
delta-9-tetrahydrocannabinol may interfere with the biological function of 18 proteins linked to schizophrenia and disrupt the synaptic transmission (dopamine, glutamine, and gamma-aminobutyric acid). |
2023-09-20 |
2023-10-07 |
Not clear |
| Claudia Sagheddu, Paola Devoto, Sonia Aroni, Pierluigi Saba, Marco Pistis, Gian Luigi Gess. Combined α Frontiers in pharmacology. vol 14. 2023-09-08. PMID:37680715. |
combined α experimental and clinical evidence indicates a deficit of release and function of dopamine in schizophrenia and suggests that α |
2023-09-08 |
2023-10-07 |
Not clear |
| M E Baklushev, M A Nazarova, P A Novikov, V V Nikuli. [Methods for assessing aberrant and adaptive salience]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 123. issue 8. 2023-09-01. PMID:37655407. |
the concepts of aberrant and adaptive salience are a kind of link between the dopamine imbalance underlying the pathogenesis of schizophrenia and the diverse clinic of the disease. |
2023-09-01 |
2023-09-07 |
Not clear |
| Licia Vellucci, Mariateresa Ciccarelli, Elisabetta Filomena Buonaguro, Michele Fornaro, Giordano D'Urso, Giuseppe De Simone, Felice Iasevoli, Annarita Barone, Andrea de Bartolomei. The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia. Biomolecules. vol 13. issue 8. 2023-08-26. PMID:37627285. |
an integrative view exploring this topic should take into account the following aspects: (i) the implication for glutamate, dopamine, and serotonin neurotransmission as demonstrated by genetic findings; (ii) the growing neuroimaging evidence of the common brain regions and dysfunctional circuits involved in both diseases; (iii) the pharmacological modulation of dopaminergic, serotoninergic, and glutamatergic systems as current therapeutic strategies in schizophrenia ocs; (iv) the recent discovery of midbrain dopamine neurons and dopamine d1- and d2-like receptors as orchestrating hubs in repetitive and psychotic behaviors; (v) the contribution of n-methyl-d-aspartate receptor subunits to both psychosis and ocd neurobiology. |
2023-08-26 |
2023-09-07 |
Not clear |
| Trevor R Norman, James S Olve. Letter to the Editor: Author reply to Letters to the Editor regarding 'A challenge to the dopamine orthodoxy in schizophrenia?' The Australian and New Zealand journal of psychiatry. 2023-08-26. PMID:37632444. |
letter to the editor: author reply to letters to the editor regarding 'a challenge to the dopamine orthodoxy in schizophrenia?' |
2023-08-26 |
2023-09-07 |
Not clear |
| Hidekazu Sotoyam. Putative neural mechanisms underlying release-mode-specific abnormalities in dopamine neural activity in a schizophrenia-like model: The distinct roles of glutamate and serotonin in the impaired regulation of dopamine neurons. The European journal of neuroscience. 2023-08-23. PMID:37611917. |
abnormalities in dopamine function might be related to psychiatric disorders such as schizophrenia. |
2023-08-23 |
2023-09-07 |
Not clear |
| Hidekazu Sotoyam. Putative neural mechanisms underlying release-mode-specific abnormalities in dopamine neural activity in a schizophrenia-like model: The distinct roles of glutamate and serotonin in the impaired regulation of dopamine neurons. The European journal of neuroscience. 2023-08-23. PMID:37611917. |
these results provide an idea about the mechanism of dopamine disturbance in schizophrenia and may be informative in explaining the effects of atypical antipsychotics as distinct from those of typical drugs. |
2023-08-23 |
2023-09-07 |
Not clear |
| Anthony A Grace, Daniela L Ulian. Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets. International journal of molecular sciences. vol 24. issue 15. 2023-08-12. PMID:37569748. |
therapeutic intervention for schizophrenia relies on blockade of dopamine d2 receptors in the associative striatum; however, there is little evidence for baseline overdrive of the dopamine system. |
2023-08-12 |
2023-08-16 |
Not clear |
| J Rafcikova, M Novakova, T Stracin. Exploring the Association between Schizophrenia and Cardiovascular Diseases: Insights into the Role of Sigma 1 Receptor. Physiological research. vol 72. issue Suppl 2. 2023-08-11. PMID:37565416. |
by modulation of the activity of several neurotransmitter systems, including dopamine, glutamate, and gaba, sigma 1 receptor might play a role in pathophysiology of schizophrenia. |
2023-08-11 |
2023-08-16 |
Not clear |
| Leslie Citrome, Jonathan M Meye. Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management. The Journal of clinical psychiatry. vol 84. issue 4. 2023-08-09. PMID:37555680. |
for decades, treatment for schizophrenia has focused on antipsychotics (aps) that reduce excess dopamine signaling to the associative striatum, which also blocks dopamine signaling in the dorsal striatum, creating movement disorders. |
2023-08-09 |
2023-08-16 |
Not clear |
| Nannan Gao, Zhipeng Liu, Hongsheng Wang, Chen Shen, Zhaoqi Dong, Wanpeng Cui, Wen-Cheng Xiong, Lin Me. Deficiency of Cullin 3, a protein encoded by a schizophrenia and autism risk gene, impairs behaviors by enhancing the excitability of ventral tegmental area (VTA) DA neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2023-08-09. PMID:37558490. |
abnormal dopamine (da) pathway is implicated in psychiatric disorders including schizophrenia (sz) and autism spectrum disorder (asd). |
2023-08-09 |
2023-08-16 |
mouse |
| Sri Jayanti, Camilla Dalla Verde, Claudio Tiribelli, Silvia Gazzi. Inflammation, Dopaminergic Brain and Bilirubin. International journal of molecular sciences. vol 24. issue 14. 2023-07-29. PMID:37511235. |
dopamine is not only involved in pd but also controls multiple mental and physical activities, such as the pleasure of food, friends and loved ones, music, art, mood, cognition, motivation, fear, affective disorders, addiction, attention deficit disorder, depression, and schizophrenia. |
2023-07-29 |
2023-08-14 |
Not clear |